Summit dumps ezutromid after phase 2 Duchenne fail | Tech News Tech News Jun 28, 2018 Despite putting up encouraging early data, Summit Therapeutics' Duchenne muscular dystrophy (DMD) drug missed its primary and secondary endpoints in a phase 2…
